The Scottish Medicines Consortium has accepted the following drugs for use within NHS Scotland:
- Triptorelin pamoate (Decapeptyl SR 22.5mg) for the management of locally advanced non-metastatic prostate cancer as an alternative to surgical castration, and the management of metastatic prostate cancer.
- Calcium carbonate + vitamin D3 (Kalcipos-D) for the prevention and treatment of calcium and vitamin D deficiency in the elderly and as an adjunct in osteoporosis.
- Mifamurtide (Mepact), in combination with post-operative multi-agent chemotherapy, for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection in children, adolescents and young adults.
- Methotrexate (Metoject) for the management of polyarthritic forms of severe active juvenile idiopathic arthritis when the response to NSAIDs has been inadequate.
- Darunavir (Prezista), in combination with ritonavir, for the treatment of HIV-1 infection in patients previously treated with antiretrovirals, with no darunavir resistance associated mutations and who have plasma HIV-1 RNA <100,000 copies/ml and CD4+ ≥100 cells/mm3.
- Nilotinib (Tasigna) for the treatment of newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia in the chronic phase.
- Capecitabine (Xeloda), in combination with oxaliplatin, for the adjuvant treatment of patients following surgery of stage 3 colon cancer.
- Filgrastim (Zarzio) for all licensed indications.
The following drugs were accepted for restricted use:
- Alteplase (Actilyse Cathflo) for the thrombolytic treatment of occluded central venous access devices, including those used for haemodialysis. Use is restricted to where alteplase is the product of choice.
- Ferric carboxymaltose (Ferinject) for the treatment of iron deficiency when oral iron is ineffective or cannot be used. Use is restricted to administration by intravenous infusion but excluding patients receiving haemodialysis.
- Tapentadol prolonged release (Palexia SR) for the management of severe chronic pain that can be managed only with opioid analgesics. Use is restricted to patients in whom modified release morphine sulphate is inadequate or not tolerated.
- Retigabine (Trobalt) for the adjunctive treatment of partial onset seizures with or without secondary generalisation. Use is restricted to refractory cases and should be initiated only by specialists.
- Omalizumab (Xolair) for the treatment of IgE-mediated asthma in adults and children over 6 years. Use is restricted to patients using chronic systemic steroids and in whom all other treatments have failed. Treatment should be discontinued if there is no marked improvement in overall asthma control at 16 weeks.
The SMC rejected paliperidone palmitate (Xeplion), collagenase Clostridium histolyticum (Xiapex) and ranibizumab (Lucentis; for the treatment of visual impairment due to retinal vein occlusion), following full submissions. Glucosamine (Glusartel), prucalopride (Resolor) and trabectedin (Yondelis) were rejected following resubmissions. No submissions were received for tadalafil (Adcirca), glucosamine (Dolenio) or bilastine (Ilaxten).
Further information: The Scottish Medicines Consortium